EUBIOLOGICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,540 KRW | +1.12% |
|
-2.66% | +18.05% |
| Jan. 29 | Zimbabwe launches door-to-door cholera vaccination campaign | RE |
| 2023 | Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial | CI |
Valuation
| Fiscal Period: December | 2020 | 2024 | 2025 |
|---|---|---|---|
| Capitalization 1 | 655,399 | 493,998 | - |
| Enterprise Value (EV) 2 | 655.4 | 508 | 508 |
| P/E ratio | - | 16.8 x | 14.6 x |
| Yield | - | - | - |
| Capitalization / Revenue | 23 x | 4.26 x | 3.86 x |
| EV / Revenue | 23 x | 4.38 x | 3.97 x |
| EV / EBITDA | - | 14.1 x | 12.7 x |
| EV / FCF | -103 x | 26.7 x | 14.5 x |
| FCF Yield | -0.97% | 3.74% | 6.89% |
| Price to Book | 7.67 x | 3.32 x | 2.7 x |
| Nbr of stocks (in thousands) | 30,770 | 36,484 | - |
| Reference price 3 | 21,300 | 13,540 | 13,540 |
| Announcement Date | 2/9/21 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2024 | 2025 |
|---|---|---|---|
| Net sales 1 | 28.49 | 116 | 128 |
| EBITDA 1 | - | 36 | 40 |
| EBIT 1 | -5.702 | 30 | 35 |
| Operating Margin | -20.01% | 25.86% | 27.34% |
| Earnings before Tax (EBT) 1 | -59.65 | 29 | 34 |
| Net income 1 | -59.65 | 29 | 34 |
| Net margin | -209.37% | 25% | 26.56% |
| EPS 2 | - | 808.0 | 928.0 |
| Free Cash Flow 3 | -6,371 | 19,000 | 35,000 |
| FCF margin | -22,361.26% | 16,379.31% | 27,343.75% |
| FCF Conversion (EBITDA) | - | 52,777.78% | 87,500% |
| FCF Conversion (Net income) | - | 65,517.24% | 102,941.18% |
| Dividend per Share | - | - | - |
| Announcement Date | 2/9/21 | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | 23.1 | 27 | 32.1 | 34.1 |
| EBITDA | - | - | - | - |
| EBIT 1 | 4.3 | 6.3 | 9.3 | 10.5 |
| Operating Margin | 18.61% | 23.33% | 28.97% | 30.79% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income 1 | 4.1 | 6.1 | 9.1 | 10.3 |
| Net margin | 17.75% | 22.59% | 28.35% | 30.21% |
| EPS | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2024 | 2025 |
|---|---|---|---|
| Net Debt 1 | - | 14 | 14 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.3889 x | 0.35 x |
| Free Cash Flow 2 | -6,371 | 19,000 | 35,000 |
| ROE (net income / shareholders' equity) | -90.2% | 22% | 20.4% |
| ROA (Net income/ Total Assets) | -47.9% | 17.2% | 16.7% |
| Assets 1 | 124.4 | 168.6 | 203.6 |
| Book Value Per Share 3 | 2,779 | 4,083 | 5,012 |
| Cash Flow per Share | -296.0 | - | - |
| Capex 1 | 8.03 | - | - |
| Capex / Sales | 28.18% | - | - |
| Announcement Date | 2/9/21 | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.05% | 365M | |
| -3.79% | 88.14B | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B |
- Stock Market
- Equities
- A206650 Stock
- Financials EuBiologics Co., Ltd.
